Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the International Vitiligo Task Force Part 1: towards a new management algorithm.

Humans Vitiligo / diagnosis Consensus Algorithms Clinical Decision-Making Surveys and Questionnaires

Journal

Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 13 02 2023
accepted: 04 08 2023
medline: 26 10 2023
pubmed: 25 9 2023
entrez: 25 9 2023
Statut: ppublish

Résumé

The treatment of vitiligo can be challenging and depends on several factors such as the subtype, disease activity, vitiligo extent, and treatment goals. Vitiligo usually requires a long-term approach. To improve the management of vitiligo worldwide, a clear and up-to-date guide based on international consensus with uniform stepwise recommendations is needed. To reach an international consensus on the nomenclature and to develop a management algorithm for the diagnosis, assessment, and treatment of vitiligo. In this consensus statement, a consortium of 42 international vitiligo experts and four patient representatives participated in online and live meetings to develop a consensus management strategy for vitiligo. At least two vitiligo experts summarized the evidence of topics included in the algorithms. A survey was utilized to resolve remaining issues among a core group of eight experts. Subsequently, the unanimous recommendations were finalized and validated based on further input from the entire group during two live meetings. The algorithms highlight the importance of shared decision-making. Dermatologists are encouraged to provide patients with detailed explanations of the prognosis and expected therapeutic outcomes based on clinical examination. The treatment goal should be discussed and clearly emphasized to patients given the different approaches for disease stabilization and repigmentation. The evaluation of disease activity remains a cornerstone in the tailor-made approach to vitiligo patients. These new treatment algorithms are intended to guide clinical decision-making in clinical practice. Promising novel therapies for vitiligo are on the horizon, further highlighting the need for reliable outcome measurement instruments and greater emphasis on shared decision-making.

Sections du résumé

BACKGROUND BACKGROUND
The treatment of vitiligo can be challenging and depends on several factors such as the subtype, disease activity, vitiligo extent, and treatment goals. Vitiligo usually requires a long-term approach. To improve the management of vitiligo worldwide, a clear and up-to-date guide based on international consensus with uniform stepwise recommendations is needed.
OBJECTIVES OBJECTIVE
To reach an international consensus on the nomenclature and to develop a management algorithm for the diagnosis, assessment, and treatment of vitiligo.
METHODS METHODS
In this consensus statement, a consortium of 42 international vitiligo experts and four patient representatives participated in online and live meetings to develop a consensus management strategy for vitiligo. At least two vitiligo experts summarized the evidence of topics included in the algorithms. A survey was utilized to resolve remaining issues among a core group of eight experts. Subsequently, the unanimous recommendations were finalized and validated based on further input from the entire group during two live meetings.
RESULTS RESULTS
The algorithms highlight the importance of shared decision-making. Dermatologists are encouraged to provide patients with detailed explanations of the prognosis and expected therapeutic outcomes based on clinical examination. The treatment goal should be discussed and clearly emphasized to patients given the different approaches for disease stabilization and repigmentation. The evaluation of disease activity remains a cornerstone in the tailor-made approach to vitiligo patients.
CONCLUSIONS CONCLUSIONS
These new treatment algorithms are intended to guide clinical decision-making in clinical practice. Promising novel therapies for vitiligo are on the horizon, further highlighting the need for reliable outcome measurement instruments and greater emphasis on shared decision-making.

Identifiants

DOI: 10.1111/jdv.19451 PMID: 37746876
pubmed: 37746876
doi: 10.1111/jdv.19451
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2173-2184

Informations de copyright

© 2023 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

Références

Picardo M, Dell'Anna ML, Ezzedine K, Hamzavi I, Harris JE, Parsad D, et al. Vitiligo. Nat Rev Dis Primers. 2015;1:15011. https://doi.org/10.1038/nrdp.2015.11
Beikert FC, Langenbruch AK, Radtke MA, Kornek T, Purwins S, Augustin M. Willingness to pay and quality of life in patients with atopic dermatitis. Arch Dermatol Res. 2014;306(3):279-286. https://doi.org/10.1007/s00403-013-1402-1
Ezzedine K, Eleftheriadou V, Jones H, Bibeau K, Kuo FI, Sturm D, et al. Psychosocial effects of vitiligo: a systematic literature review. Am J Clin Dermatol. 2021;22(6):757-774. https://doi.org/10.1007/s40257-021-00631-6
Taieb A, Alomar A, Böhm M, Dell'anna M, de Pase A, Eleftheriadou V, et al. Guidelines for the management of vitiligo: the European dermatology forum consensus. Br J Dermatol. 2013;168(1):5-19. https://doi.org/10.1111/j.1365-2133.2012.11197.x
Oiso N, Suzuki T, Wataya-Kaneda M, Tanemura A, Tanioka M, Fujimoto T, et al. Guidelines for the diagnosis and treatment of vitiligo in Japan. J Dermatol. 2013;40(5):344-354. https://doi.org/10.1111/1346-8138.12099
Eleftheriadou V, Atkar R, Batchelor J, McDonald B, Novakovic L, Patel JV, et al. British Association of Dermatologists guidelines for the management of people with vitiligo 2021. Br J Dermatol. 2022;186(1):18-29. https://doi.org/10.1111/bjd.20596
Böhm M, Schunter JA, Fritz K, Salavastru C, Dargatz S, Augustin M, et al. S1 guideline: diagnosis and therapy of vitiligo. J Dtsch Dermatol Ges. 2022;20(3):365-378. https://doi.org/10.1111/ddg.14713
Speeckaert R, van Geel N. Vitiligo: an update on pathophysiology and treatment options. Am J Clin Dermatol. 2017;18(6):733-744. https://doi.org/10.1007/s40257-017-0298-5
Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. https://doi.org/10.1016/S0140-6736(14)60763-7
Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CCE, et al. Revised classification/nomenclature of vitiligo and related issues: the vitiligo global issues consensus conference. Pigment Cell Melanoma Res. 2012;25(3):E1-E13. https://doi.org/10.1111/j.1755-148X.2012.00997.x
van Geel N, Hamzavi I, Kohli I, Wolkerstorfer A, Lim HW, Bae JM, et al. Standardizing serial photography for assessing and monitoring vitiligo: a core set of international recommendations for essential clinical and technical specifications. J Am Acad Dermatol. 2020;83(6):1639-1646. https://doi.org/10.1016/j.jaad.2019.10.055
Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the vitiligo area scoring index. Arch Dermatol. 2004;140(6):677-683. https://doi.org/10.1001/archderm.140.6.677
Taïeb A, Picardo M, VETF Members. The definition and assessment of vitiligo: a consensus report of the vitiligo European task force. Pigment Cell Res. 2007;20(1):27-35. https://doi.org/10.1111/j.1600-0749.2006.00355.x
van Geel N, Lommerts J, Bekkenk M, Wolkerstorfer A, Prinsen CAC, Eleftheriadou V, et al. Development and validation of the vitiligo extent score (VES): an international collaborative initiative. J Invest Dermatol. 2016;136(5):978-984. https://doi.org/10.1016/j.jid.2015.12.040
van Geel N, Wolkerstorfer A, Lommerts JE, Ezzedine K, Eleftheriadou V, Hamzavi I, et al. Validation study of the vitiligo extent score-plus. J Am Acad Dermatol. 2018;78(5):1013-1015. https://doi.org/10.1016/j.jaad.2017.11.032
van Geel N, Bekkenk M, Lommerts JE, Ezzedine K, Harris J, Hamzavi I, et al. The vitiligo extent score (VES) and the VESplus are responsive instruments to assess global and regional treatment response in patients with vitiligo. J Am Acad Dermatol. 2018;79(2):369-371. https://doi.org/10.1016/j.jaad.2017.12.070
Komen L, da Graça V, Wolkerstorfer A, de Rie MA, Terwee CB, van der Veen JPW. Vitiligo area scoring index and vitiligo European task force assessment: reliable and responsive instruments to measure the degree of depigmentation in vitiligo. Br J Dermatol. 2015;172(2):437-443. https://doi.org/10.1111/bjd.13432
van Geel N, Lommerts JE, Bekkenk MW, Prinsen CA, Eleftheriadou V, Taieb A, et al. Development and validation of a patient-reported outcome measure in vitiligo: the self assessment vitiligo extent score (SA-VES). J Am Acad Dermatol. 2017;76(3):464-471. https://doi.org/10.1016/j.jaad.2016.09.034
van Geel N, Vandendriessche D, Vandersichel E, De Schepper S, Grine L, Mertens L, et al. Reference method for digital surface measurement of target lesions in vitiligo: a comparative analysis. Br J Dermatol. 2019;180(5):1198-1205. https://doi.org/10.1111/bjd.17190
van Geel N, Wolkerstorfer A, Ezzedine K, Pandya AG, Bekkenk M, Grine L, et al. Validation of a physician global assessment tool for vitiligo extent: results of an international vitiligo expert meeting. Pigment Cell Melanoma Res. 2019;32(5):728-733. https://doi.org/10.1111/pcmr.12784
van Geel N, Moock C, Zuidgeest M, Uitentuis SE, Wolkerstorfer A, Speeckaert R. Patients' perception of vitiligo severity. Acta Derm Venereol. 2021;101(6):adv00481. https://doi.org/10.2340/00015555-3823
van Geel N, Uitentuis SE, Zuidgeest M, Wolkerstorfer A, Bekkenk MW, Moock C, et al. Validation of a patient global assessment for extent, severity and impact to define the severity strata for the self assessment vitiligo extent score (SA-VES). J Eur Acad Dermatol Venereol. 2021;35(1):216-221. https://doi.org/10.1111/jdv.16562
Sosa JJ, Currimbhoy SD, Ukoha U, Sirignano S, O'Leary R, Vandergriff T, et al. Confetti-like depigmentation: a potential sign of rapidly progressing vitiligo. J Am Acad Dermatol. 2015;73(2):272-275. https://doi.org/10.1016/j.jaad.2015.05.014
van Geel N, Grine L, De Wispelaere P, Mertens D, Prinsen CAC, Speeckaert R. Clinical visible signs of disease activity in vitiligo: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019;33(9):1667-1675. https://doi.org/10.1111/jdv.15604
Zhang L, Chen S, Kang Y, Wang X, Yan F, Jiang M, et al. Association of Clinical Markers with Disease Progression in patients with vitiligo from China. JAMA Dermatol. 2020;156(3):288-295. https://doi.org/10.1001/jamadermatol.2019.4483
van Geel N, Passeron T, Wolkerstorfer A, Speeckaert R, Ezzedine K. Reliability and validity of the vitiligo signs of activity score (VSAS). Br J Dermatol. 2020;183(5):883-890. https://doi.org/10.1111/bjd.18950
van Geel N, Depaepe L, Vandaele V, Mertens L, van Causenbroeck J, de Schepper S, et al. Assessing the dynamic changes in vitiligo: reliability and validity of the vitiligo disease activity score (VDAS) and vitiligo disease improvement score (VDIS). J Eur Acad Dermatol Venereol. 2022;36(8):1334-1341. https://doi.org/10.1111/jdv.18134
Ezzedine K, Ahmed M, Tovar-Garza A, Hajj C, Whitton M, Pandya A, et al. Cross-cultural validation of a short-form of the vitiligo impact patient scale (VIPs). J Am Acad Dermatol. 2019;81(5):1107-1114. https://doi.org/10.1016/j.jaad.2019.02.008
Salzes C, Abadie S, Seneschal J, Whitton M, Meurant JM, Jouary T, et al. The vitiligo impact patient scale (VIPs): development and validation of a vitiligo burden assessment tool. J Invest Dermatol. 2016;136(1):52-58. https://doi.org/10.1038/JID.2015.398
Lilly E, Lu PD, Borovicka JH, Victorson D, Kwasny MJ, West DP, et al. Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL). J Am Acad Dermatol. 2013;69(1):e11-e18. https://doi.org/10.1016/j.jaad.2012.01.038
Gupta V, Sreenivas V, Mehta M, Khaitan BK, Ramam M. Measurement properties of the vitiligo impact Scale-22 (VIS-22), a vitiligo-specific quality-of-life instrument. Br J Dermatol. 2014;171(5):1084-1090. https://doi.org/10.1111/bjd.13093
Picardo M, Huggins RH, Jones H, Marino R, Ogunsola M, Seneschal J. The humanistic burden of vitiligo: a systematic literature review of quality-of-life outcomes. J Eur Acad Dermatol Venereol. 2022;2:1507-1523. https://doi.org/10.1111/jdv.18129
Chernyshov PV, Tomas-Aragones L, Manolache L, Pustisek N, Salavastru CM, Marron SE, et al. Quality of life measurement in vitiligo. Position statement of the European academy of dermatology and venereology task force on quality of life and patient oriented outcomes with external experts. J Eur Acad Dermatol Venereol. 2023;37(1):21-31. https://doi.org/10.1111/jdv.18593
Mulekar SV, Al Eisa A, Delvi MB, Al Issa A, Al Saeed AH. Childhood vitiligo: a long-term study of localized vitiligo treated by noncultured cellular grafting. Pediatr Dermatol. 2010;27(2):132-136. https://doi.org/10.1111/j.1525-1470.2009.00978.x
Esmat SM, Bassiouny D, Hegazy R, Shalaby S, Ragab N, Ibrahim S, et al. Early localized vitiligo, a medical emergency: long-term follow-up study. Dermatol Ther. 2022;35(2):e15219. https://doi.org/10.1111/dth.15219
van Geel NAC, Mollet IG, De Schepper S, Tjin EPM, Vermaelen K, Clark RA, et al. First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. Pigment Cell Melanoma Res. 2010;23(3):375-384. https://doi.org/10.1111/j.1755-148X.2010.00703.x
Gan EY, Eleftheriadou V, Esmat S, Hamzavi I, Passeron T, Böhm M, et al. Repigmentation in vitiligo: position paper of the vitiligo global issues consensus conference. Pigment Cell Melanoma Res. 2017;30(1):28-40. https://doi.org/10.1111/pcmr.12561
Brazzelli V, Antoninetti M, Palazzini S, Barbagallo T, De Silvestri A, Borroni G. Critical evaluation of the variants influencing the clinical response of vitiligo: study of 60 cases treated with ultraviolet B narrow-band phototherapy. J Eur Acad Dermatol Venereol. 2007;21(10):1369-1374. https://doi.org/10.1111/j.1468-3083.2007.02278.x
Shourick J, Ahmed M, Seneschal J, Passeron T, Andreux N, Qureshi A, et al. Development of a shared decision-making tool in vitiligo: an international study. Br J Dermatol. 2021;185(4):787-796. https://doi.org/10.1111/bjd.20137
Passeron T, Ostovari N, Zakaria W, Fontas E, Larrouy JC, Lacour JP, et al. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol. 2004;140(9):1065-1069. https://doi.org/10.1001/archderm.140.9.1065
Westerhof W, Nieuweboer-Krobotova L, Mulder PG, Glazenburg EJ. Left-right comparison study of the combination of fluticasone propionate and UV-A vs. either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. Arch Dermatol. 1999;135(9):1061-1066. https://doi.org/10.1001/archderm.135.9.1061
Lee JH, Kwon HS, Jung HM, Lee H, Kim GM, Yim HW, et al. Treatment outcomes of topical Calcineurin inhibitor therapy for patients with vitiligo: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(8):929-938. https://doi.org/10.1001/jamadermatol.2019.0696
Bae JM, Yoo HJ, Kim H, Lee JH, Kim GM. Combination therapy with 308-nm excimer laser, topical tacrolimus, and short-term systemic corticosteroids for segmental vitiligo: a retrospective study of 159 patients. J Am Acad Dermatol. 2015;73(1):76-82. https://doi.org/10.1016/j.jaad.2015.04.008
Pandya AG, Harris JE, Lebwohl M, Hamzavi IH, Butler K, Kuo FI, et al. Addition of narrow-band ultraviolet light B (UVB) phototherapy to Ruxolitinib cream in patients with vitiligo. J Invest Dermatol. 2022;142:3352-3355.e4. https://doi.org/10.1016/j.jid.2022.05.1093
Middelkamp-Hup MA, Bos JD, Rius-Diaz F, Gonzalez S, Westerhof W. Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study. J Eur Acad Dermatol Venereol. 2007;21(7):942-950. https://doi.org/10.1111/j.1468-3083.2006.02132.x
Fontas E, Montaudié H, Passeron T. Oral gliadin-protected superoxide dismutase in addition to phototherapy for treating non-segmental vitiligo: a 24-week prospective randomized placebo-controlled study. J Eur Acad Dermatol Venereol. 2021;35(8):1725-1729. https://doi.org/10.1111/jdv.17331
Jung HM, Jung YS, Lee JH, Kim GM, Bae JM. Antioxidant supplements in combination with phototherapy for vitiligo: a systematic review and metaanalysis of randomized controlled trials. J Am Acad Dermatol. 2021;85(2):506-508. https://doi.org/10.1016/j.jaad.2018.10.010
Radakovic-Fijan S, Fürnsinn-Friedl AM, Hönigsmann H, Tanew A. Oral dexamethasone pulse treatment for vitiligo. J Am Acad Dermatol. 2001;44(5):814-817. https://doi.org/10.1067/mjd.2001.113475
Nicolaidou E, Antoniou C, Stratigos AJ, Stefanaki C, Katsambas AD. Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy. J Am Acad Dermatol. 2007;56(2):274-278. https://doi.org/10.1016/j.jaad.2006.09.004
Cavalié M, Ezzedine K, Fontas E, Montaudié H, Castela E, Bahadoran P, et al. Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study. J Invest Dermatol. 2015;135(4):970-974. https://doi.org/10.1038/jid.2014.527
Nguyen S, Chuah SY, Fontas E, Khemis A, Jhingan A, Thng STG, et al. Atorvastatin in combination with narrowband UV-B in adult patients with active vitiligo: a randomized clinical trial. JAMA Dermatol. 2018;154(6):725-726. https://doi.org/10.1001/jamadermatol.2017.6401
Tovar-Garza A, Hinojosa JA, Hynan LS, Pandya AG. Addition of oral minipulse dexamethasone to narrowband ultraviolet B phototherapy and topical steroids helps arrest disease activity in patients with vitiligo. Br J Dermatol. 2019;180(1):193-194. https://doi.org/10.1111/bjd.17150
Esmat SM, El-Mofty M, Rasheed H, Mostafa WZ, Anbar TS, Abdallah M, et al. Efficacy of narrow band UVB with or without OMP in stabilization of vitiligo activity in skin photo-types (III-V): a double-blind, randomized, placebo-controlled, prospective, multicenter study. Photodermatol Photoimmunol Photomed. 2022;38(3):277-287. https://doi.org/10.1111/phpp.12749
Lommerts JE, Njoo MD, de Rie MA, Wolkerstorfer A, Bekkenk MW. Twenty-year follow-up using a postal survey of childhood vitiligo treated with narrowband ultraviolet B phototherapy. Br J Dermatol. 2017;177(3):e60-e61. https://doi.org/10.1111/bjd.15337
Gill BS, Brar MS, Chaudhary N, Randhawa A. Non-cultured melanocyte transfer in the management of stable vitiligo. J Family Med Prim Care. 2019;8(9):2912-2916. https://doi.org/10.4103/jfmpc.jfmpc_546_19
Löntz W, Olsson MJ, Moellmann G, Lerner AB. Pigment cell transplantation for treatment of vitiligo: a progress report. J Am Acad Dermatol. 1994;30(4):591-597. https://doi.org/10.1016/s0190-9622(94)70067-2
Verma SB. Vitiligo precipitated by striae: a little known entity. J Eur Acad Dermatol Venereol. 2009;23(3):357-358. https://doi.org/10.1111/j.1468-3083.2008.02844.x
Park KY, Kwon HJ, Wie JH, Lee HH, Cho SB, Kim BJ, et al. Pregnancy outcomes in patients with vitiligo: a nationwide population-based cohort study from Korea. J Am Acad Dermatol. 2018;79(5):836-842. https://doi.org/10.1016/j.jaad.2018.02.036
Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst Rev. 2015;2015:CD007346. https://doi.org/10.1002/14651858.CD007346.pub3

Auteurs

Nanja van Geel (N)

Department of Dermatology, Ghent University Hospital, Ghent, Belgium.
ORCID: 0000-0002-3249-8195

Reinhart Speeckaert (R)

Department of Dermatology, Ghent University Hospital, Ghent, Belgium.

Alain Taïeb (A)

Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hospital Saint-André, BRIC, UMR 1312, Inserm, University Bordeaux, Bordeaux, France.
ORCID: 0000-0002-0928-8608

Khaled Ezzedine (K)

Department of Dermatology, University Hospital Henri Mondor, EpiDermE EA 7379, Université Paris-Est Créteil Val de Marne, Créteil, France.
ORCID: 0000-0002-5468-4589

Henry W Lim (HW)

Department of Dermatology, Henry Ford Health, Detroit, Michigan, USA.

Amit G Pandya (AG)

Department of Dermatology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
ORCID: 0000-0002-3916-2651

Thierry Passeron (T)

Department of Dermatology, University Hospital of Nice, Nice, France.
ORCID: 0000-0002-0797-6570

Albert Wolkerstorfer (A)

Department of Dermatology, Ghent University Hospital, Ghent, Belgium.
Department of Dermatology, Netherlands Institute for Pigment Disorders, Amsterdam University Medical Centers, Amsterdam Institute for Infection and Immunity, University of Amsterdam, Amsterdam, The Netherlands.

Marwa Abdallah (M)

Dermatology, Andrology, and Venereology Department, Ain Shams University, Cairo, Egypt.
ORCID: 0000-0002-7791-9141

Augustin Alomar (A)

Department of Dermatology, Clinica Dermatologica Moragas, Barcelona, Spain.

Jung Min Bae (JM)

Department of Dermatology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
ORCID: 0000-0001-5975-8519

Marcel Bekkenk (M)

Department of Dermatology, Netherlands Institute for Pigment Disorders, Amsterdam University Medical Centers, Amsterdam Institute for Infection and Immunity, VU University, Amsterdam, The Netherlands.

Laila Benzekri (L)

Department of Dermatology, Ibn Sina University Hospital, Mohammed V University, Rabat, Morocco.
ORCID: 0000-0003-1885-6563

Markus Böhm (M)

Department of Dermatology, University Hospital Münster, Münster, Germany.
ORCID: 0000-0001-7338-7734

Viktoria Eleftheriadou (V)

New Cross Hospital, The Royal Wolverhampton NHS Trust, Wolverhampton, UK.

Samia Esmat (S)

Department of Dermatology, Faculty of Medicine, Cairo University, Cairo, Egypt.

Deepti Ghia (D)

Department of Dermatology, Jaslok Hospital and Research Hospital and South Mumbai Dermatology Clinic, Mumbai, India.

Boon Kee Goh (BK)

Skin Physicians Pte Ltd, Mount Elizabeth Medical Centre, Singapore City, Singapore.

Pearl Grimes (P)

Vitiligo & Pigmentation Institute of Southern California, Los Angeles, California, USA.

Somesh Gupta (S)

Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.
ORCID: 0000-0003-3015-8602

Iltefat H Hamzavi (IH)

Department of Dermatology, Henry Ford Health, Detroit, Michigan, USA.

John E Harris (JE)

Department of Dermatology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.

Sang Ho Oh (SH)

Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, South Korea.
ORCID: 0000-0002-4477-1400

Richard Huggins (R)

Department of Dermatology, Henry Ford Health, Detroit, Michigan, USA.

Ichiro Katayama (I)

Pigmentation Research and Therapeutics, Osaka Metropolitan University, Osaka, Japan.

Eric Lan (E)

Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
ORCID: 0000-0003-4654-118X

Ai-Young Lee (AY)

Department of Dermatology, College of Medicine, Dongguk University Ilsan Hospital, Goyang, Korea.

Giovanni Leone (G)

Photodermatology and Vitiligo Treatment Unit, Israelite Hospital, Roma, Italy.

Caroline Le Poole (C)

Departments of Dermatology, Microbiology and Immunology, Robert H. Lurie Comprehensive Cancer Center Northwestern University, Chicago, Illinois, USA.

Harvey Lui (H)

Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada.

Nicolle Maquignon (N)

Association Française du Vitiligo, Paris, France.

Jean Marie Meurant (JM)

Vitiligo International Patient Organisations Committee, Paris, France.

Paul Monteiro (P)

Vitiligo.nl, Den Haag, The Netherlands.

Naoki Oiso (N)

Department of Dermatology, Kindai University Nara Hospital, Ikoma, Japan.
ORCID: 0000-0001-5593-6496

Davinder Parsad (D)

Department of Dermatology, Venereology & Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
ORCID: 0000-0001-9820-7875

Georg Pliszewski (G)

Deutscher Vitiligo-Bund e.V., Adelsdorf, Germany.

Noufal Raboobee (N)

Department of Dermatology, Westville Hospital, Durban, South Africa.

Michelle Rodrigues (M)

Chroma Dermatology, Pigment and Skin of Colour Centre, Parkville, Victoria, Australia.
Department of Dermatology, The Royal Children's Hospital, Parkville, Victoria, Australia.
ORCID: 0000-0002-9747-1882

David Rosmarin (D)

Department of Dermatology, Tufts University School of Medicine, Boston, Massachusetts, USA.

Tamio Suzuki (T)

Department of Dermatology, Yamagata University Faculty of Medicine, Yamagata, Japan.

Atsushi Tanemura (A)

Department of Dermatology Integrated Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
ORCID: 0000-0002-5239-8474

Steven Thng (S)

Skin Research Institute of Singapore, ASTAR, Singapore City, Singapore.

Flora Xiang (F)

Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
ORCID: 0000-0002-2712-3962

Youwen Zhou (Y)

Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada.

Mauro Picardo (M)

Unicamillus International University, Rome, Italy.

Julien Seneschal (J)

Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin disorders, Hospital Saint-André, University of Bordeaux, CNRS UMR 5164, ImmunoConcept, Bordeaux, France.
ORCID: 0000-0003-1139-0908

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Worldwide expert recommendations for the...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Hypopigmentation › Vitiligo › Worldwide expert recommendations for the...
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Pensée (activité mentale) › Prise de décision › Consensus › Worldwide expert recommendations for the...
questionsmedicales.fr › Sciences de l'information › Méthodologies informatiques › Algorithmes › Worldwide expert recommendations for the...
questionsmedicales.fr › Diagnostic › Prise de décision clinique › Worldwide expert recommendations for the...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Enquêtes et questionnaires › Worldwide expert recommendations for the...